Jiangsu Recbio Technology (HKG:2179) initiated a phase III clinical trial in China for its Shingles vaccine REC610 and achieved the first subject enrollment, according to a Wednesday filing on the Hong Kong bourse.
The REC610 clinical trial application was approved by China's National Medical Products Administration (NMPA) in October last year.
The vaccine prevents Shingles, a common viral infectious disease that may cause post-herpetic neuralgia (PHN), which results in severe neuralgia.
Price (HKD): $8.50, Change: $-0.090, Percent Change: -1.05%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments